Magnesium sulfate neuroprotection in preterm infants
Phase 3
Recruiting
- Conditions
- Infant immaturity.Preterm [premature] newborn [other]P07.3
- Registration Number
- IRCT20120826010664N5
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 246
Inclusion Criteria
Singleton pregnancy
Spontaneous labor
Gestational age between 32 and 36 weeks
Exclusion Criteria
Maternal underlying diseases
Fetal abnormalities
Intrauterine growth retardation (IUGR)
Contraindications for use of magnesium sulfate
Iatrogenic preterm birth
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eurodevelopmental status of infants (including APGAR score, Arterial blood pH after the birth, and Neurodevelopment status after the age of 4 months). Timepoint: 0, 4, 6, 8, 10, and 12 months after the birth. Method of measurement: Blood test and standard Ages & Stages Questionnaires (ASQ).
- Secondary Outcome Measures
Name Time Method